Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells

Journal of Biochemistry

Volumn 147, Issue 5, 2010, Pages 671-678

  Oka, Saori ^a   Kimura, Shinji ^a   Toshida, Toshinobu ^a   Ota, Ryo ^a   Yamashita, Atsushi ^a   Sugiura, Takayuki ^a  

^a TEIKYO UNIVERSITY   (Japan)

Author keywords

activating transcription factor 2; cannabinoid; G protein coupled receptor; lysophosphatidylinositol; p38 mitogen activated protein kinase

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ACTIVATING TRANSCRIPTION FACTOR 2; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; LYSOPHOSPHATIDYLINOSITOL; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL; RHO KINASE; UNCLASSIFIED DRUG; AMIDE; ATF2 PROTEIN, HUMAN; CANNABINOID RECEPTOR; GPR55 PROTEIN, HUMAN; LIGAND; LYSOPHOSPHOLIPID; MESSENGER RNA; PYRIDINE DERIVATIVE;

ARTICLE; CELL STRAIN HEK293; CELLULAR STRESS SIGNAL; CONTROLLED STUDY; GENETIC TRANSFECTION; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; LYMPHOBLASTOID CELL; LYMPHOID ORGAN; MAMMAL CELL; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SPLEEN; STIMULATION; THYMUS; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL LINE; DOSE RESPONSE; DRUG EFFECTS; GENETICS; METABOLISM; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRUCTURE ACTIVITY RELATION;

MAMMALIA;

ACTIVATING TRANSCRIPTION FACTOR 2; AMIDES; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIGANDS; LYSOPHOSPHOLIPIDS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PYRIDINES; RECEPTORS, CANNABINOID; RECEPTORS, G-PROTEIN-COUPLED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77952954092     PISSN: 0021924X     EISSN: 17562651     Source Type: Journal    
DOI: 10.1093/jb/mvp208     Document Type: Article

References (35)

1. Howlett, A.C., Barth, F., Bonner, T.I., Cabral, G., Casellas, P., Devane, W.A., Felder, C.C., Herkenham, M., Mackie, K., Martin, B.R., Mechoulam, R., and Pertwee, R.G. (2002) International Union of Pharmacology: XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54, 161-202
2. Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C., and Bonner, T.I. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564
3. Munro, S., Thomas, K.L., and Abu-Shaar, M. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65
4. Di Marzo, V., De Petrocellis, L., Fezza, F., Ligresti, A., and Bisogno, T. (2002) Anandamide receptors. Prostaglandins Leukot. Essent. Fatty Acids 66, 377-391
5. Di Marzo, V. and De Petrocellis, L. (2006) Non-CB1, non-CB2 receptors for endocannabinoids in Endocannabinoids: The Brain and Body's Marijuana and Beyond (Onaivi, E.S., Sugiura, T., and Di Marzo, V., eds.), pp. 151-174, Taylor & Francis, Boca Raton.
6. Begg, M., Pacher, P., Bá tkai, S., Osei-Hyiaman, D., Offertá ler, L., Mo, F.M., Liu, J., and Kunos, G. (2005) Evidence for novel cannabinoid receptors. Pharmacol. Ther. 106, 133-145
7. Sawzdargo, M., Nguyen, T., Lee, D.K., Lynch, K.R., Cheng, R., Heng, H.H., George, S.R., and O'Dowd, B.F. (1999) Identification and cloning of three novel human G protein-coupled receptor genes GPR52, wGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res. Mol. Brain Res. 64, 193-198
8. Brown, A.J. and Wise, A. (2001) Identification of Modulators of GPR55 Activity. GlaxoSmithKline, Patent number, WO0186305
9. Drmota, T., Greasley, P., and Groblewski, T. (2004) Screening Assays for Cannabinoid-ligand-type Modulators of GPR55. Astrazeneca, Patent number, WO2004074844
10. Johns, D.G., Behm, D.J., Walker, D.J., Ao, Z., Shapland, E.M., Daniels, D.A., Riddick, M., Dowell, S., Staton, P.C., Green, P., Shabon, U., Bao, W., Aiyar, N., Yue, T.-L., Brown, A.J., Morrison, A.D., and Douglas, S.A. (2007) The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br. J. Pharmacol. 152, 825-831
11. Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N.-O., Leonova, J., Elebring, T., Nilsson, Drmota, T., and Greasley, P.J. (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 152, 1092-1101
12. Petitet, F., Donlan, M., and Michel, A. (2006) GPR55 as a new cannabinoid receptor: still a long way to prove it. Chem. Biol. Drug Des. 67, 252-253
13. Baker, D., Pryce, G., Davies, W.L., and Hiley, C.R. (2006) In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol. Sci. 27, 1-4
14. Oka, S., Nakajima, K., Yamashita, A., Kishimoto, S., and Sugiura, T. (2007) Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem. Biophys. Res. Commun. 362, 928-934
15. Hiley, C.R. and Kaup, S.S. (2007) GPR55 and the vascular receptors for cannabinoids. Br. J. Pharmacol. 152, 559-561
16. Pertwee, R.G. (2007) GPR55: a new member of the cannabinoid receptor clan? Br. J. Pharmacol. 152, 984-986
17. Brown, A.J. (2007) Novel cannabinoid receptors. Br. J. Pharmacol. 152, 567-575
18. Lauckner, J.E., Jensen, J.B., Chen, H.-Y., Lu, H.-C., Hille, B., and Mackie, K. (2008) GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl Acad. Sci. USA 105, 2699-2704
19. Waldeck-Weiermair, M., Zoratti, C., Osibow, K., Balenga, N., Goessnitzer, E., Waldhoer, M., Malli, R., and Graier, W.F. (2008) Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J. Cell Sci. 121, 1704-1717
20. Oka, S., Toshida, T., Maruyama, K., Nakajima, K., Yamashita, A., and Sugiura, T. (2009) 2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55. J. Biochem. 145, 13-20
21. Henstridge, C.M., Balenga, N.A., Ford, L.A., Ross, R.A., Waldhoer, M., and Irving, A.J. (2009) The GPR55 ligand L-a-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J. 23, 183-193
22. Yin, H., Chu, A., Li, W., Wang, B., Shelton, F., Otero, F., Nguyen, D.G., Caldwell, J.S., and Chen, Y.A. (2009) Lipid G protein-coupled receptor ligand identification using b-arrestin PathHunter assay. J. Biol. Chem. 284, 12328-12338
23. Ross, R.A. (2009) The enigmatic pharmacology of GPR55. Trends Pharmacol. Sci. 30, 56-63
24. Godllewski, G., Offertá ler, L., Wagner, J.A., and Kunos, G. (2009) Receptors for acylethanolamides - GPR55 and GPR119. Prostaglandins Other Lipid Mediat. 89, 105-111
25. Pietr, M., Kozela, E., Levy, R., Rimmerman, N., Lin, Y.H., Stella, N., Vogel, Z., and Juknat, A. (2009) Differential changes in GPR55 during microglial cell activation. FEBS Lett. 583, 2071-2076
26. Gupta, S., Campbell, D., Dé rijard, B., and Davis, R.J. (1995) Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 267, 389-393
27. Ouwens, D.M., de Ruiter, N.D., van der Zon, G.C., Carter, A.P., Schouten, J., van der Burgt, C., Kooistra, K., Bos, J.L., Maassen, J.A., and van Dam, H. (2002) Growth factors can activate ATF2 via a two-step mechanism: phosphorylation of Thr71 through the Ras-MEK-ERK pathway and of Thr69 through RalGDS-Src-p38. EMBO J. 21, 3782-3793
28. Davies, S.P., Reddy, H., Caivano, M., and Cohen, P. (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95-105
29. Marinissen, M.J., Chiariello, M., and Gutkind, J.S. (2001) Regulation of gene expression by the small GTPase Rho through the ERK6 (p38 g) MAP kinase pathway. Genes Dev. 15, 535-553
30. Kozasa, T., Jiang, X., Hart, M.J., Sternweis, P.M., Singer, W.D., Gilman, A.G., Bollag, G., and Sternweis, P.C. (1998) p115 RhoGEF, a GTPase activating protein for Ga12 and Ga13. Science 280, 2109-2111
31. Hart, M.J., Jiang, X., Kozasa, T., Roscoe, W., Singer, W.D., Gilman, A.G., Sternweis, P.C., and Bollag, G. (1998) Direct stimulation of the guanine nucleotide exchange activity of p115 RhoGEF by Ga13. Science 280, 2112-2114
32. Staton, P.C., Hatcher, J.P., Walker, D.J., Morrison, A.D., Shapland, E.M., Hughes, J.P., Chong, E., Mander, P.K., Green, P.J., Billinton, A., Fulleylove, M., Lancaster, H.C., Smith, J.C., Bailey, L.T., Wise, A., Brown, A.J., Richardson, J.C., and Chessell, I.P. (2008) The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 139, 225-236
33. Kumar, S., Boehm, J., and Lee, J.C. (2003) p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat. Rev. Drug Discov. 2, 717-726
34. Ashwell, J.D. (2006) The many paths to p38 mitogen-activated protein kinase activation in the immune system. Nat. Rev. Immunol. 6, 532-540
35. Corda, D., Iurisci, C., and Berrie, C.P. (2002) Biological activities and metabolism of the lysophosphoinositides and glycerophosphoinositols. Biochim. Biophys. Acta 1582, 52-69